Global Irritable Bowel Syndrome (IBS) Market Study 2015-2025, by Segment (IBS-D Drug, IBS-C Drug, Others), by Market (Women, Men), by Company (Valeant Pharmaceuticals, Allergan, Takeda)

ReportPage
Report ID
24557
Published Date
28-Oct
No of Report Page
60
Report Category
Editor's Rating
US $3,600.00
US $3,600.00
US $1,800.00

  • Report Details

    Snapshot
    Irritable bowel syndrome (IBS) is defined as recurrent abdominal pain or discomfort that occurs in association with altered bowel habits over a period of at least 3 months. The disorder is classified into three main subtypes, according to the predominant bowel habits presented: constipation-predominant IBS (IBS-C), diarrhea-predominant IBS (IBS-D), and mixed-presentation IBS (IBS-M). IBS

    More...
  • Table Of Content

    Table of Content
    1 Industry Overview
    1.1 Irritable Bowel Syndrome (IBS) Industry
    1.1.1 Overview
    1.1.2 Products of Major Companies
    1.2 Market Segment
    1.2.1 Industry Chain
    1.2.2 Consumer Distribution
    1.3 Price & Cost Overview
    2 Irritable Bowel Syndrome (IBS) Market by Type
    2.1 By Type
    2.1.1 IBS-D Drug
    2.1.2 IBS-C Drug
    2.1.3 Others

    More...
  • Inquiry Before Buying
    Inquiry Before Buying -
  • Request Sample
    Request For Sample